Evidence map›Paper›PMID 37009524›Full record

ArticleResearch methods in medicine & health sciences2023

Statistical assessment of the prognostic and the predictive value of biomarkers-A biomarker assessment framework with applications to traumatic brain injury biomarker studies.

Leonidas E Bantis, Kate J Young, John V Tsimikas, Brian R Mosier, Byron Gajewski, Sharon Yeatts, Renee L Martin, William Barsan, Robert Silbergleit, Gaylan Rockswold and 1 more

Registry-linked trialOpen access · greenAbstract read
In one paragraph

Article in Research methods in medicine & health sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02407028 (Hyperbaric Oxygen Brain Injury Treatment), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02407028 phase2recruitingnot on this map

Hyperbaric Oxygen Brain Injury Treatment (HOBIT) Trial

TypeinterventionalSponsorGaylan RockswoldRan2018 to 2029Enrolled200ConditionsTraumatic Brain InjuryArmsHyperbaric oxygen (1.5 ATA, no NBH), Hyperbaric oxygen (2.0 ATA, no NBH), Hyperbaric oxygen (2.5 ATA, no NBH), Hyperbaric oxygen (1.5 ATA + NBH), Hyperbaric oxygen (2.0 ATA + NBH)
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Observational
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Leonidas E BantisDepartment of Biostatistics & Data Science, University of Kansas Medical Center, Kansas City, KS, USA.
Kate J YoungDepartment of Biostatistics & Data Science, University of Kansas Medical Center, Kansas City, KS, USA.
John V TsimikasDepartment of Statistics and Actuarial-Financial Mathematics, University of the Aegean, School of Sciences, Samos, Greece.
Brian R MosierDepartment of Biostatistics & Data Science, University of Kansas Medical Center, Kansas City, KS, USA.
Byron GajewskiDepartment of Biostatistics & Data Science, University of Kansas Medical Center, Kansas City, KS, USA.ORCID 0000-0001-7589-8247
Sharon YeattsDepartment of Public Health Sciences, Medical University of South Carolina, Charleston, SC, USA.
Renee L MartinDepartment of Public Health Sciences, Medical University of South Carolina, Charleston, SC, USA.
William BarsanDepartment of Emergency Medicine University, Michigan Medical School, University of Michigan, Ann Arbor, MI, USA.
Robert SilbergleitDepartment of Emergency Medicine University, Michigan Medical School, University of Michigan, Ann Arbor, MI, USA.
Gaylan RockswoldDepartment of Neurosurgery, University of Minnesota, Hennepin County Medical Center, Minneapolis, MN, USA.
Frederick K KorleyDepartment of Emergency Medicine University, Michigan Medical School, University of Michigan, Ann Arbor, MI, USA.
University of Kansas Medical Center · USUniversity of Michigan · USMedical University of South Carolina · USUniversity of Minnesota · USUniversity of the Aegean · GR

Funding

RADx-UP: Improving the Response of Local Urban and Rural Communities to Disparities in Covid-19 TestingUL1TR002366 · NCATS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI Mario Castro, JAMES STEVEN LEEDER · 2017 to 2026
$44.3M
Using Integrated Omics to Identify Dysfunctional Genetic Mechanisms Influencing Schizophrenia and Sleep DisturbancesP20GM130423 · NIGMS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI ANDREW K. GODWIN · 2019 to 2026
$21.5M
Hyperbaric Oxygen Brain Injury Treatment (HOBIT) Trial - CCCU01NS095926 · NINDS · HENNEPIN HEALTHCARE RESEARCH INSTITUTE · PI Byron J. Gajewski, Frederick Kofi Korley · 2017 to 2026
$12.3M
Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) - Data Coordinating CenterU24NS100655 · NINDS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI VALERIE L DURKALSKI, Sharon Dziuba Yeatts · 2017 to 2026
$4.4M
Extracellular Vesicle Proteomic Fingerprinting of Ovarian Cancer for Early Detection with a Nanoengineered MicrosystemR01CA260132 · NCI · UNIVERSITY OF KANSAS MEDICAL CENTER · PI GODWIN, ANDREW K., ZENG, YONG · 2021 to 2025
$3.4M
Biomarkers in the Hyperbaric Oxygen in Brain Injury Treatment TrialR01NS114251 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Frederick Kofi Korley · 2020 to 2026
$3.0M
Hyperbaric Oxygen BrainInjury Treatment (HOBIT) Trial-SDMC Supplement FITBIRU01NS095814 · NINDS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI MARTIN, RENEE HEBERT · 2017 to 2022
$2.3M
NCATS NIH HHS UL1 TR002366NCI NIH HHS R01 CA260132NIGMS NIH HHS P20 GM130423NINDS NIH HHS R01 NS114251NINDS NIH HHS U01 NS095814NINDS NIH HHS U01 NS095926NINDS NIH HHS U24 NS100655
6 · The paper itself

Abstract

Studies that investigate the performance of prognostic and predictive biomarkers are commonplace in medicine. Evaluating the performance of biomarkers is challenging in traumatic brain injury (TBI) and other conditions when both the time factor (i.e. time from injury to biomarker measurement) and different levels or doses of treatments are in play. Such factors need to be accounted for when assessing the biomarker's performance in relation to a clinical outcome. The Hyperbaric Oxygen in Brain Injury Treatment (HOBIT) trial, a phase II randomized control clinical trial seeks to determine the dose of hyperbaric oxygen therapy (HBOT) for treating severe TBI that has the highest likelihood of demonstrating efficacy in a phase III trial. Hyperbaric Oxygen in Brain Injury Treatment will study up to 200 participants with severe TBI. This paper discusses the statistical approaches to assess the prognostic and predictive performance of the biomarkers studied in this trial, where prognosis refers to the association between a biomarker and the clinical outcome while the predictiveness refers to the ability of the biomarker to identify patient subgroups that benefit from therapy. Analyses based on initial biomarker levels accounting for different levels of HBOT and other baseline clinical characteristics, and analyses of longitudinal changes in biomarker levels are discussed from a statistical point of view. Methods for combining biomarkers that are of complementary nature are also considered and the relevant algorithms are illustrated in detail along with an extensive simulation study that assesses the performance of the statistical methods. Even though the discussed approaches are motivated by the HOBIT trial, their applications are broader. They can be applied in studies assessing the predictiveness and prognostic ability of biomarkers in relation to a well-defined therapeutic intervention and clinical outcome.

Indexed as

Biomarker combinationsgeneralized estimating equationlongitudinal biomarkerpredictive biomarkerprognostic biomarkerreceiver operating characteristisensitivityspecificity

Identifiers

PMID37009524
PMCPMC10061824
OpenAlexW4311312919

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.